Clinical Effects of Pulse High-Volume Hemofiltration on Severe Acute Pancreatitis Complicated With Multiple Organ Dysfunction Syndrome

Therapeutic Apheresis and Dialysis

Volumn 17, Issue 1, 2013, Pages 78-83

  Chu, La Ping ^a   Zhou, Jun Jing ^a   Yu, Ya Fen ^a   Huang, Yang ^a   Dong, Wen Xia ^a  

^a Soochow University   (China)

Author keywords

Continuous veno venous hemofiltration; Hemodynamics; Inflammatory factor; Multiple organ dysfunction syndrome; Pulse high volume hemofiltration; Severe acute pancreatitis

Indexed keywords

AMYLASE; ANTICOAGULANT AGENT; C REACTIVE PROTEIN; DOPAMINE; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL BLEEDING; ACUTE PANCREATITIS; ADULT; AMYLASE BLOOD LEVEL; ANTICOAGULANT THERAPY; APACHE; ARTICLE; BILIARY TRACT DISEASE; BODY TEMPERATURE; BODY WEIGHT; CATHETER INFECTION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTINUOUS HEMOFILTRATION; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HEART RATE; HEMODYNAMICS; HEMOFILTRATION; HUMAN; HYPERLIPIDEMIA; LEUKOCYTE COUNT; LIPID DIET; MALE; MEAN ARTERIAL PRESSURE; MORTALITY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; PULSE HIGH VOLUME HEMOFILTRATION; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SHOCK; SIMPLIFIED ACUTE PHYSIOLOGY SCORE;

ACUTE DISEASE; ADULT; APACHE; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOFILTRATION; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PANCREATITIS; SEVERITY OF ILLNESS INDEX; SHOCK; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84873470909     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2012.01104.x     Document Type: Article

References (26)

1. Jiang K, Chen XZ, Xia Q etal. Early nasogastric enteral nutrition for severe acute pancreatitis: a systematic review. World J Gastroenterol 2007;13:5253-60.
2. Carnovale A, Rabitti PG, Manes G etal. Mortality in acute pancreatitis: is it an early or a late event? JOP 2005;6:438-44.
3. Sheiko VD, Panasenko SI, Dolthkaovyi SV. Mortality analysis in acute severe pancreatitis using objective assessment of the patient state severity and polyorgan dysfunction. Klin Khir 2011;8:25-7.
4. Whitcomb DC. Clinical practice. Acute pancreatitis. N Engl J Med 2006;354:2142-50.
5. Malangoni MA, Martin AS. Outcome of severe acute pancreatitis. Am J Surg 2005;189:273-7.
6. Li WQ, Tong ZH, Quan ZF etal. Treatment experience of severe acute pancreatitis on 1033 cases. Zhonghua Wai Ke Za Zhi. 2009;47:1472-82.
7. Pupelis G, Zeiza K, Plaudis H etal. Conservative approach in the management of severe acute pancreatitis: eight-year experience in a single institution. HPB 2008;10:347-55.
8. Pupelis G, Plaudis H, Grigane A etal. Continuous veno-venous haemofiltration in the treatment of severe acute pancreatitis: 6-year experience. HPB 2007;9:295-301.
9. Li W, Yan X, Wang H etal. Effects of continuous high-volume hemofiltration on experimental severe acute pancreatitis in pigs. Pancreas 2007;34:112-19.
10. Brendolan A, D'Intini V, Ricci Z etal. Pulse high volume hemofiltration. Int J Artif Organs 2004;27:398-403.
11. Bone RC, Balk RA, Cerra FB etal. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644-55.
12. Acevedo Tizón A, Targarona Modena J, Málaga Rodríguez G etal. Identifying the severe acute pancreatitis. Rev Gastroenterol Peru 2011;31:236-40.
13. Bhatia M, Wong FL, Cao Y etal. Pathophysiology of acute pancreatitis. Pancreatology 2005;5:132-44.
14. Jiang K, Chen XZ, Xia Q etal. Early veno-venous hemofiltraton for severe acute pancreatitis: a systematic review. Zhongguo Xunzheng Yixue Zazhi 2007;7:121-34.
15. Ogawa M. Acute pancreatitis and cytokines: "second attack" by septic complication leads to organ failure. Pancreas 1998;16:312-15.
16. Mayer J, Rau B, Gansauge F etal. Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications. Gut 2000;47:546-52.
17. Baldwin I, Bellomo R, Naka T etal. A pilot randomized controlled comparison of extended daily dialysis with filtration and continuous veno-venous hemofiltration: fluid removal and hemodynamics. Int J Artif Organs 2007;30:1083-9.
18. Yekebas EF, Treede H, Knoefel WT etal. Influence of zero-balanced hemofiltration on the course of severe experimental pancreatitis in pigs. Ann Surg 1999;229:514-22.
19. Rogiers P, Zhang H, Smail N etal. Continuous venovenous hemofiltration improves cardiac performance by mechanisms other than tumor necrosis factor-alpha attenuation during endotoxic shock. Crit Care Med 1999;27:1848-55.
20. Bellomo R, Kellum JA, Gandhi CR etal. The effect of intensive plasma water exchange by hemofiltration on hemodynamics and soluble mediators in canine endotoxemia. Am J Respir Crit Care Med 2000;161:1429-36.
21. Cole L, Bellomo R, Journois D etal. High-volume haemofiltration in human septic shock. Intensive Care Med 2001;27:978-86.
22. Joannes-Boyau O, Rapaport S, Bazin R etal. Impact of high volume hemofiltration on hemodynamic disturbance and outcome during septic shock. ASAIO J 2004;50:102-9.
23. Ratanarat R, Brendolan A, Piccinni P etal. Pulse high-volume hemofiltration for treatment of severe sepsis: effects on hemodynamics and survival. CriticalCare 2005;9:R294-R302.
24. Ghani RA, Zainudin S, Ctkong N etal. Serum IL-6 and IL-1-ra with sequential organ failure assessment scores in septic patients receiving high-volume haemofiltration and continuous venovenous haemofiltration. Nephrologie 2006;11:386-93.
25. Sander A, Armbruster W, Sander B etal. Hemofiltration increases IL-6 clearance in early systemic inflammatory response syndrome but does not alter IL-6 and TNF plasma concentrations. Intensive Care Med 1997;23:878-84.
26. Klouche K, Cavadore P, Portales P etal. Continuous venovenous hemofiltration improves hemodynamics in septic shock with acute renal failure without modifying TNF-a and IL-6 plasma concentrations. J Nephrol 2002;15:150-7.